Randomised phase II trial of weekly ixabepilone ± biweekly bevacizumab for platinum-resistant or refractory ovarian/fallopian tube/primary peritoneal cancer-Reference-Cited by-同舟云学术

Randomised phase II trial of weekly ixabepilone ± biweekly bevacizumab for platinum-resistant or refractory ovarian/fallopian tube/primary peritoneal cancer

Published:2022-02-11 Issue:12 Volume:126 Page:1695-1703
ISSN:0007-0920
Container-title:British Journal of Cancer
language:en
Short-container-title:Br J Cancer

Author:

Roque Dana M.^ORCID,Siegel Eric R.,Buza Natalia^ORCID,Bellone Stefania,Silasi Dan-Arin,Huang Gloria S.^ORCID,Andikyan Vaagn,Clark Mitchell,Azodi Masoud,Schwartz Peter E.,Rao Gautam G.,Reader Jocelyn C.,Hui Pei,Tymon-Rosario Joan R.,Harold Justin,Mauricio Dennis,Zeybek Burak,Menderes Gulden,Altwerger Gary,Ratner Elena,Santin Alessandro D.^ORCID

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology

Link

https://www.nature.com/articles/s41416-022-01717-6.pdf

Reference80 articles.

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70:7–30.

2. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394–424.

3. Jayson GC, Kohn EC, Kitchener HC, Ledermann JA. Ovarian cancer. Lancet. 2014;384:1376–88.

4. Pujade-Lauraine E, Hilpert F, Weber B, Reuss A, Poveda A, Kristensen G, et al. Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the AURELIA open-label randomized phase III trial. J Clin Oncol. 2014;32:1302–8.

5. Wysham WZ, Schaffer EM, Coles T, Roque DR, Wheeler SB, Kim KH. Adding bevacizumab to single agent chemotherapy for the treatment of platinum-resistant recurrent ovarian cancer: a cost effectiveness analysis of the AURELIA trial. Gynecol Oncol. 2017;145:340–5.

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Randomized phase II trial of weekly ixabepilone ± biweekly bevacizumab for platinum-resistant or refractory ovarian/fallopian tube/primary peritoneal cancer (NCT03093155): Updated survival and subgroup analyses;BJC Reports;2024-06-20

2. Efficacy and safety of anti-angiogenic drug monotherapy and combination therapy for ovarian cancer: a meta-analysis and trial sequential analysis of randomized controlled trials;Frontiers in Pharmacology;2024-05-27

3. Randomized phase II trial of weekly ixabepilone ± biweekly bevacizumab for platinum- resistant or refractory ovarian / fallopian tube / primary peritoneal cancer (NCT03093155): updated survival and subgroup analyses;2024-05-21

4. Correction: Randomised phase II trial of weekly ixabepilone ± biweekly bevacizumab for platinum-resistant or refractory ovarian/fallopian tube/primary peritoneal cancer;British Journal of Cancer;2024-03-04

5. Efficacy and safety of VEGF/VEGFR inhibitors for platinum-resistant ovarian cancer: a systematic review and meta-analysis of randomized controlled trials;BMC Women's Health;2024-01-13